Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex Dosing by Weight in Morbidly Obese Patients
NCT03381209Completed
- Sponsor
- Ain Shams University
- Start
- Jun 2017
- Primary completion
- Nov 2017
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of Sugammadex in neuromuscular blockade (NMB) (3 arms), sponsored by Ain Shams University. Primary endpoint: Time from administration of Sugammadex to train of four (TOF) ratio >= 0.9 at 5 minutes. Started Jun 2017; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03381209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381209.